Blog Archives

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

CertaraJanuary 26, 2026

Blog

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…

CertaraJanuary 16, 2026

Blog

The Rise of Biologics Discovery: From Small Molecules to Sequences

Biologics in drug discovery is becoming more important by the year. See where biologics discovery…

CertaraJanuary 15, 2026

Blog

Transform PK/PD Workflows with Automation and Integration

Reduce delays and errors in PK/PD workflows. See where workflows stall, from data prep to…

CertaraJanuary 14, 2026

Blog

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…

CertaraDecember 29, 2025

Blog

How to build standardized eCRFs across multiple EDC systems

Discover how to build standardized eCRFs across multiple EDC systems to improve data quality, accelerate…

CertaraDecember 12, 2025

Blog

7 key annotated CRF regulatory submission requirements you should know

Discover 7 key aCRF regulatory submission requirements for delivering high-quality annotated CRFs, including real-world examples…

Gilbert HunterDecember 10, 2025

Blog

Virtual Triplets: The Next Step in Personalized and Ethical Drug Development

Learn how virtual triplets, linking PBPK, QSP, and organ-on-a-chip technologies, are transforming model-informed drug development,…

CertaraDecember 9, 2025

Blog

Tautomer Generation Methods – Case Study on Reliability

Tautomer data handling in a reliable manner - case study based on thorough testing to…

CertaraDecember 4, 2025

Blog

The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation

The stepwise Paediatric Investigation Plan (PIP) is a strategic, flexible route for drug developers navigating…

CertaraNovember 26, 2025

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

The Rise of Biologics Discovery: From Small Molecules to Sequences

Transform PK/PD Workflows with Automation and Integration

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

How to build standardized eCRFs across multiple EDC systems

7 key annotated CRF regulatory submission requirements you should know

Virtual Triplets: The Next Step in Personalized and Ethical Drug Development

Tautomer Generation Methods – Case Study on Reliability

The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation

Newsletter sign up

Quick links

Solutions

Contact